Brainstorm Cell Therapeutics INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OQB
Brainstorm Cell Therapeutics Inc. reported continued operating losses and a substantial accumulated deficit in its Q2 2026 filing, highlighting ongoing capital needs and challenges following its Nasdaq delisting.
OQB
Brainstorm Cell Therapeutics faces Nasdaq delisting, ongoing legal challenges, and significant capital needs despite progress in NurOwn's Phase 3b trial design for ALS.
OQB
Brainstorm Cell Therapeutics reported Q2 2025 financial results, detailing its Nasdaq delisting, ongoing clinical progress for NurOwn in ALS, and significant capital raising activities amidst continued operating losses.
OQB
Brainstorm Cell Therapeutics announces its Q1 2025 financial results, highlighting ongoing efforts to regain Nasdaq compliance and advance its NurOwn program.
OQB
Brainstorm Cell Therapeutics reported its third quarter 2024 results, highlighting a decrease in operating expenses and progress in its NurOwn clinical program, while also addressing ongoing financial and legal challenges.
OQB
Brainstorm Cell Therapeutics reported its financial results for the second quarter of 2024, highlighting a decrease in operating expenses and progress in its NurOwn clinical program, including a Special Protocol Assessment (SPA) agreement with the FDA.
OQB
Brainstorm Cell Therapeutics announced its first quarter 2024 financial results and highlighted a Special Protocol Assessment (SPA) agreement with the FDA for its NurOwn Phase 3b trial in ALS.